Biotech Leaders agenda

Capital markets, investment, partnerships, deal making & more



Day 1 – Wednesday 3rd May

09:00 LSX Welcome Address

Adam Griffiths, Senior Conference Director, Biotech Lead, LSX

09:05 Assessing Biotech Investment Trends in 2023 & Beyond

  • State of biopharma sector today – top line, bottom line, financial markets
  • Contemporary deal flow vs. historical norms
  • Impact of rally / downturn at time of presentation - how will other variables follow - IPO, private rounds
  • Boomerang to early-stage deals versus later stage deals
  • Inflation Reduction Act – impact on the sector, how companies are responding

Cody Powers, Principal - Portfolio & Pipeline, ZS Associates

Cody Powers, Principal - Portfolio & Pipeline, ZS Associates

09:30 Panel: Building Global Biotech Leader of Tomorrow – Shaping the Next Phase of Europe’s Booming Biotech Ecosystem

A tectonic shift in the biotech financing environment in recent years reached an all-time high of $104.7 billion, as biotech IPOs reached record levels in 2021 – 143 offerings totalling $19.3 billion. Fast forward through 2022, listings have dried up, valuations have dropped, and companies are faced with more difficult access to both private and public capital leaving some companies facing existential challenges. The unforeseeable geopolitical environment along with the post-pandemic landscape created difficult market conditions and new challenges, leaving the industry faced with more uncertainty in the immediate future; the skills to navigate these unprecedented challenges will be essential for the biotech C-suite. Executives of Europe’s leading life biotech companies, investors, and key stakeholders discuss the next wave of new challenges facing biotech leaders in 2023 and beyond, evidence of Europe’s successes, and potential improvements of the industry to strategically build an ever-stronger globally competitive powerhouse.

  • What are the financing challenges 2023 and what can we learn from 2022 to be better prepared for uncertainty?
  • Reduced access to capital forced a barrage of restructurings and a potential increased desirability for acquisition. While an M&A rebound is expected, is that a reality?
  • Access to the US market and building a transatlantic footprint remains paramount but where has Europe excelled and demonstrated leadership?
  • How are fund changing their allocation of capital? Does the way that funds are structured create an intrinsic problem for the industry?

Moderator: Mark Dorff, Partner, Brown Rudnick
Ryan Richardson,
Chief Strategy Officer, BioNTech
Nanna Lüneborg,
General Partner, Forbion
Andrew Levin,
Managing Partner, RA Capital Management
Laura Lane, VP, Venture Sciences (Europe Head), Eli Lilly

Mark Dorff, Partner, Brown RudnickRyan Richardson, Chief Strategy Officer, BioNTechNanna Lüneborg, General Partner, ForbionAndrew Levin, Managing Partner, RA Capital ManagementLaura Lane, VP Venture Sciences - Europe, Lilly

10:30 Morning Break



11:10 Panel: Leading the Way in Today’s Global Investment Landscape – New Innovations, Strategies and Future Outlook

It’s no secret that the funding environment took a major shock and reset in 2022. However, no matter what the current geopolitical climate or state of the capital markets, innovation continues at ever-increasing speed and this innovation needs funding. Investors continue to raise record breaking levels of capital from LPs through new and recharged funds, so will 2023 see an upturn? Unexpected events create unexpected challenges, and unexpected challenges breed new opportunities. Leading investors discuss the global investment landscape and shifts in public and private finance, as well as what they expect 2023 and onwards to hold.

  • Where are the safe havens, if any, during uncertain times?
  • Perspectives on the public markets and the trickle-down effect on private funding
  • Is the investment community now prioritising early-stage investments?
  • Is competition for deals higher than ever? What can biotech companies, whatever stage they are at, do to ensure they are most attractive for investment?
Moderator: Gregory Benning, Managing Director & Head of Investment Banking, Back Bay Life Science Advisors
Stephen Squinto,
CIO, JP Morgan Life Sciences Private Capital
Hakan Goker, MD, M Ventures
John Cassidy, Investment Director Life Sciences & HealthTech, Softbank Vision Fund

Gregory Benning, Managing Director, Group Head - Investment Banking, Back Bay Life ScienceStephen Squinto, Chief Investment Officer, JP Morgan Life Sciences Private CapitalHakan Goker, Managing Director, M VenturesJohn Cassidy, Investment Director Life Sciences & HealthTech, Softbank Vision Fund

11:50 Cureline’s journey from the US to Europe, setting up R&D in Lithuania

Hear firsthand from Cureline, a leading human biospecimen CRO, that recently decided to invest in Lithuania. Get an exclusive insight into:

  • Cureline’s clinical R&D strategy and the factors that made them choose Lithuania as its base for R&D.
  • Discover why Lithuania has become an attractive destination for R&D-based operations.
  • Hear about financial incentives available for R&D and manufacturing projects directly from Invest Lithuania representative.
Julija Lukaityte, Senior Investment Advisor – Biotech and Pharma, Invest Lithuania
Olga Potapova, CEO, Cureline

Julija Lukaityte, Senior Investment Advisor – Biotech and Pharma, Invest LithuaniaOlga Potapova, CEO, Cureline

12:10 Panel: Investing in the New Landscape – Future Directions in Neurodegenerative Disease

Recognition that aging populations will give rise to new healthcare needs, and heightened awareness of mental health issue, is bringing renewed focus to neurological health. Dementia is the most common degenerative neurological condition in the United States, with most cases coming from Alzheimer’s disease. In 2021, 653 clinical development programs for medicines to treat neurological diseases, 43% of which are for neurodegenerative medicines. An expert panel discusses the investment needed to overcome these obstacles and explore the future of NDD research financing and commercialisation.

  • Current neurodegenerative drug development bottlenecks and progressing beyond them
  • Exploring transformative new platforms on the horizon for Alzheimer’s, ALS, Parkinson’s, Huntington’s and more
  • How to effectively incorporate novel research into drug development approach to maximize success commercially and in the clinic
  • How new mechanisms and modalities have opened doors for early-stage investment
  • Public market reception for neuro focused companies and the effect on M&A
Moderator Madeleine Armstrong, News Editor, Evaluate Vantage
David Reynolds, CEO, LoQus23
Jenny Barnett, CEO, Monument Therapeutics
Laurence Barker, Partner Dementia Discovery Fund, SV Health Investors
Arno de Wilde, Director, EQT Life Sciences
Hugh Nuthall, Senior Director, S&E, Eli Lilly

Madeleine Armstrong, News Editor, VantageDavid Reynolds, CEO, LoQus 23Jenny Barnett, CEO, Monument TxLaurence Barker, CCBO, DDF, SV Health Investors 300xArno de Wilde, Director, EQT Life SciencesHugh Nuthall, Senior Director, Search & Evaluation Neuroscience, Eli Lilly and Company



11:10 Panel: The Next Era of Vaccinology: How Partnerships are Shaping the Future of Infectious Diseases

It has been a landmark year for vaccines with continued development of next-generation platforms and vaccines for unmet needs. What comes next? Opportunities to develop global partnerships and collaboration is clearer than ever. A panel of trail-blazing experts share experience and insights and on the future of this technology and wider therapeutic area of infectious diseases.

  • How can new partnerships be leveraged to boost success?
  • How do we sustain R&D innovation?
  • The need for new human trial regulations to test vaccine efficacy – alternative routes to licensure?
  • What are the next most exciting opportunities in infectious diseases?
Moderator: Zara Asgharpour, Executive Director, Head of External Innovations, Lonza
Holger Kissel, VP Business Alliances, BioNTech
Stig Tollefsen, Technology Office Lead, CEPI
Chris Cardon, CEO, Ziphius Vaccines
Ike James, Head of Technology Transfer, Medicines Patent Pool
Ulrich Osswald, VP of Licensing, Lonza

_Zara Asgharpour, Executive Director, Head of External Innovations, LonzaHolger Kissel, Vice President, Business Alliances, BioNTechStig Tollefsen, Technology Office Lead, Coalition for Epidemic Preparedness Innovations (CEPI)Chris Cardon, CEO, Ziphius VaccinesIlk James, Head of Technology Transfer, Medicines Patent PoolUlrich Osswald, VP of Licensing, Lonza

12:00 Panel: Future Horizons in Oncology Therapeutics and Global Deal-Making

Approved cell therapies have generated more than $2 billion in sales, and with novel oncology drugs being launched at an increasing rate there is more opportunity today for oncology partnering than ever before.. New technologies and techniques offer the potential to address diseases with significant unmet needs (such as solid tumors, which represent more than 90 percent of adult cancers) and non-oncological conditions., however significant challenges remain which hinder a broader use.
  • Assessing the growing market for oncology drugs
  • The types of products are oncology drug marketers are looking for and typical deal terms
  • Current roadblocks, activities, and opportunities in oncology partnering in 2023
  • Significant trends in oncology deal-making and identifying remaining areas of unmet medical need
Moderator: Victoria English, Co-founder and Editor, MedNous
Jie D’Elia, SVP BD,Oncology & Haematology, Bristol Myers Squibb
Chris Brown,
Senior Director Oncology Worldwide BD, GSK
Faical Miyara,
Global Head Oncology Partnering, Ipsen
Sonal Patel,
VP Scientific Innovation Oncology, Johnson & Johnson Innovation

Victoria English, Co-founder and Editor, MedNousJie D’Elia, SVP Business Development, Oncology & Haematology, Bristol Myers SquibbChris Brown, Senior Director, Oncology Worldwide Business Development, GSK Faical Miyara, Global Head Oncology Partnering, IpsenSonal Patel, Vice President, Scientific Innovation, Oncology, Johnson & Johnson


11:10 Go-It-Alone or Partner? A Review of First Launch and Partnering Trends

In Europe or the US, more than a 100 emerging biotech and pharmaceutical companies have commercialized themselves for the first time since 2011.  Should we launch ourselves, co-promote, our out-license in key regions?  This is one of the most strategic set of choices facing development-stage biotechs. What has been the experience of first-launch companies in rare disease, oncology and other therapeutic areas?  How are companies adapting to a more challenging funding environment? We will share an insight and benchmark-packed short presentation to set the stage for an expert panel discussion.  This is a must attend session for companies considering commercializing themselves. We will discuss: 

  • A look at more than a decade of data for the US and EU markets (solo first launch, co-promote, out-license and key benchmarks)
  • A spotlight on lean commercialization models and launches <$500M in peak sales
  • Partnering across the R&D value chain
  • Expert panel discussion and Q&A

Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates

Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates

11:30 Panel: First Launch and Partnering Trends

  • Can we “go it alone”, and what have existing companies done?
  • Partnering across the R&D value chain
  • Should we partner in Europe, the US, or Japan/Asia?
  • Preparing to launch – what and when? “Table stakes” vs differentiating?
  • What best practices and innovations should we aspire for?
Moderator: Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates
Erik van den Berg, CEO, AM-Pharma
Matthias Evers, CBO, Evotec
Helen Ho, Chief Business Officer, Blueprint Medicines

Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS AssociatesErik_van_den_Berg-261x300Matthias Evers, CBO, EvotecHelen Ho, Chief Business Officer, Blueprint Medicines

12:00 Panel: Biotech Valuation Tips, Tricks & Best Practices – Increasing the Value of your Company

Biotech companies with little to no revenue can still be worth billions. Despite facing some stiff headwinds, the biotech sector remains a strong engine for innovation, and small and emerging companies account for more than 50% of the current research and development pipeline. In uncertain times, with a market downturn and difficult geopolitical situations, how can a biotech company look to increase its value?

  • Why we need to understand biotech valuation, and why biotech pipeline valuation is different
  • Drug roulette? Switching business models to circumvent difficulties
  • Alternative strategies to increase value of the company

Moderator: Katy Georgiadis, Senior Consultant, Halloran Consulting
Sven Kili, CEO, Antion Biosciences
Duncan Young, Head of Business Development, Redx Pharma
Bev Carr, CBO, Amphista Therapeutics
Giulia Vestri, Head of Business Development, Azafaros

Katy Georgiadis, Senior Consultant, Halloran ConsultingSven Kili, CEO, AntionDuncan Young, Sr. Director Business Development & Licencing, AstraZenecaBev Carr, CBO, Amphista TherapeuticsGiulia Vestri, Head of Business Development, Azafaros

12.50 Lunch Break

14:00 Panel: Early-stage Investment: What’s the New Normal for Biotech Funding?

Venture-capital funding and valuations for biotechnology start-ups remain high despite economic turmoil. For emerging biotech start-up companies, funding is one of the first challenges they will face and can influence the long-term success of a company. Spurred by the Covid-19 pandemic, new approaches to treating cancer, inflammatory diseases and other conditions have arrived, but how are they being sourced and funded?
A panel of expert early-stage investors with a keen eye for innovation discuss the latest innovations that excite them, their advice for biotech execs, and best practice in raising funds and positioning yourself as a leading, young company.

  • What are the top priority areas for investment and how are the latest discoveries and technological advances being sourced?
  • What are some of the factors which a company should possess to indicate they can be an attractive investment?
  • How will biotech early-stage funding change in the coming year?
  • How can founders and biotech execs prepare for the future?
Moderator: Samana Brannigan, Head of Health Technologies, UKRI
Alex Hamilton,
Partner, Syncona
Mary Canning,
Principal, Epidarex Capital
Jeroen Bakker,
Principal, Novo Seeds
Martin Pfister, Principal, High-Tech Gründerfonds

Samana Brannigan, Innovation Lead and Investor Relations, Innovate UK 300xAlex Hamilton, Partner, SynconaMary Canning, Principal, Epidarex CapitalJeroen Bakker, Principle, Novo Seeds, Nova HoldingsMartin Pfister, Investment Manager, High-Tech Gründerfonds

14:50 Panel: What I Wish I Had Known When Taking Assets to the US Market

Entering new markets comes with many challenges; intellectual property (IP) licensing, transactions, agreements – the list goes on. Entering the US market is becoming a strategic consideration ever-earlier in the growth process for many biotech companies, and experience, knowledge, and effective due diligence in navigating the whole process can save time, money, and headaches down the line. A multi-stakeholder panel will discuss how companies and their investors can optimize their IP portfolios for entry to the US, ensure long-term success in securing capital from investors, prepare for licensing and transactions, and minimize litigation risk.

  • How to put yourself in the best possible position for investment and deals
  • What assets investors and partners will want to see in your IP portfolio
  • How to protect privileged and confidential information during the due diligence process
  • Experience and lessons learned about ‘what I wish I had known’ and ‘what I think I could have done better’
Moderator: Gwilym Attwell, Patent Attorney, Fish & Richardson
Kieran Rooney, SVP, Head of BD, Amryt Pharma
Damien O’Farrell, Assistant General Counsel (Patents), GSK
Melya Hughes Crameri, Partner, Ventac Partners
Richard Bungay, CEO, Imophoron

Gwilym Attwell, Principal, Fish & RichardsonKieran Rooney, VP, Strategic Alliances and Licensing, Amryt PharmaDamien O’Farrell, Assistant General Counsel (Patents), GSKMelya Hughes Crameri Female FoundersRichard Bungay, Interim CEO, Diurnal


14:00 Panel: Accelerating Gene Therapies for Rare Disease Patients – Where Are the Bottlenecks & How Can We Overcome Them

New partnerships continue to emerge within the gene therapy field, but the past year has also flagged distinct development challenges that need to be overcome. Experts from pioneering companies and leading pharma the way to pinpoint these obstacles and explore how we can address them to bring gene therapies to patients more quickly, safely, and effectively:

  • Adapting to the novelty of gene therapies with respect to regulatory, pricing, market access, and patient needs
  • Accelerating gene therapy programs while maintaining safety and quality standards
  • How new partnerships are being leveraged to advance the field
  • Building out internal manufacturing capacity for commercial products
  • Exploring the concept of centres of excellence versus multi-centre gene therapy
Lori Badura, VP, Head of Global Neuroscience & Rare Disease Partnering, Ipsen
Jean-Philippe Combal,
CEO, Vivet Therapeutics
Francis Pang
, SVP, Global Market Access & Geographical Expansion, Orchard Therapeutics
Thomas Tan, Principal, Sound Bioventures

Lori Badura, Global Head of Neurology and Immunology Business Development, Merck KGaAJean-Philippe Combal, CEO, Vivet TherapeuticsFrancis Pang, SVP, Global Market Access & Geographical Expansion, Orchard TherapeuticsThomas Tan, Principal, Sound Bioventures

14:40 Debiopharm’s unique partnering approach to maximise patient access across the globe

With an emphasis on both in- and out-licensing, Debiopharm’s unique approach to forming partnerships bridges the gap between disruptive discovery products and real-world patient reach. With strong experience in clinical development manufacturing, attend this presentation to hear:

  • Debiopharm’s licensing strategy, including both in- and out-licensing 
  • The different types of partnerships which are possible
  • Real-world examples of regional to global deals

Sandra von Meier, Head BD & Licensing, Debiopharm International 

Sandra von Meier, Head Business Development & Licensing, Debiopharm International

15:00 Panel: Immuno-Inflammation: A Doorway to New Partners and Therapeutic Areas

Various dysfunctions in the immune system are the underlying cause for many health conditions, thus researching the mechanisms that drive these diseases can provide new insights across multiple therapeutic areas, ranging from neurodegenerative to cardiovascular diseases. Immuno-inflammation can also serve as a starting point leading to non-traditional partnerships between pharma, biotech, and research organisations. This panel gathers companies active in immunology & inflammation, discussing how they use this cross-indication response to identify R&D opportunities and inform their BD strategies.

  • How can we gain a better understanding of our patients’ journeys to achieve enhanced outcomes?
  • How can identifying new R&D opportunities inform BD strategies?
  • What partnerships can we form with patient groups, research institutions, public health authorities, and others in the industry across diseases?
  • What new innovations are coming down the pipeline, and how is the field as a whole developing? What are the future directions?
Toby Richardson, Senior Director, Early Innovation Partnering Immunology, EMEA, J&J Innovation
Rachel Strick, Head of Immunology BD & Acquisitions, AbbVie
Peng Leong, Chief Business Officer, BioAge Labs
Vishal Sahni, Director, Corporate Business Development & Strategy, Lundbeck

Toby Richardson, Senior Director, Early Innovation Partnering Immunology, EMEA, J&J InnovationRachel Strick, Head of Immunology Business Development & Acquisitions, AbbViePeng Leong, Chief Business Officer, BioAge Labs
Vishal Sahni, Director, Corporate Business Development & Strategy, Lundbeck


14:00 Ensuring A Swift And Successful Launch - Early Commercial Innovation & Planning

It may have previously been the norm to focus on clinical development and to leave commercial thinking to a bigger partner. However, as more and more companies choose to go it alone, or to do later stage deals, there is a need for asset owners to have a more granular understanding of their target market, the needs of their stakeholders, and the evidence required to ensure successful uptake and long-term differentiation

  • Forming your target product profiles and development strategy
  • Generating key data and information at every part of the development path
  • Having a commercial strategy to work towards and selling this to stakeholders, investors and
Moderator: Grace Lomax, Corporate Development, Clarivate
Dmitry Paramonov, Head of US Commercial Organisation, ​Orphalan
Ian Crosbie, CEO, Sequana Medical
James Barder, CEO, Futura Medical
Renee Aguiar-Lucander, CEO, Calliditas

Grace Lomax,  Corporate Development, ClarivateDmitry Paramonov, Head of US Commercial Organisation, ​OrphalanIan Crosbie, CEO Sequana MedicalJames Barder, CEO, Futura MedicalRenee Aguiar-Lucander, CEO, Calliditas Therapeutics

14:40 Fast-Tracking Drug Development Through Understanding Key Decision Factors When Outsourcing to CRO

CRO have operated on a business model which predominantly focused on serving as external service providers for manufacturing mature pharmaceuticals, however in recent years a dramatic shift in business models have occurred. CRO have increasingly become leaders of innovation and are covering more areas of the Drug Development pipeline from discovery and pre-clinical through the clinical phases to post commercialisation – but what does this mean for biotech and pharma?

  • Changing customer requirements leads to a change in business models
  • The role of CROs in the production of medicines today.
  • How these changes can be valuable to biotech and pharma

Jette Cowan, Head of Commercial – Pharmaceuticals, RSSL

Jette Cowan, Head Of Commercial – Pharmaceuticals, RSSL

15:00 Panel: Optimising the Value of your Asset For Entry Into the US and EU/UK Markets

Achieving a commercial transatlantic presence as a biotech company requires gaining regulatory approvals, and a successful launch of the product on the markets.  The development of a clear roadmap with the right strategy to overcome challenges will increase the value of your assets and can dramatically reduce the time taken to reach market.

  • How to translate what we hear from regulatory bodies and payers/HTA bodies to inform our own internal decision-making?
  • Major differences between US and EU/UK that you need to consider during development
  • Lessons learned and tangible takeaways anyone can apply to their programs, today.
Moderator: Thomas Lönngren, Strategic Advisor, NDA Group
Lisa Campbell, Medical Advisor, NDA Group
Trevor Mill, Chief Development Officer, COMPASS Pathways
Mel Walker, Managing Director, BioPharma Futures

 Thomas Lönngren, Strategic Advisor, NDA GroupLisa Campbell, Medical Advisor, NDA GroupTrevor Mill, Chief Development Officer at COMPASS PathwaysMel Walker, Managing Director, BioPharma Futures-2

15.40 Afternoon Break

16.20 Afternoon Keynote: Pharma’s New Era

The biopharma industry has weathered some storms in recent times, but the innovation, success stories and development of life saving treatments and cures continue to inspire. A ship is only as good as its captain and on rough seas and changing currents, strong leadership must endure.
  • Reimagining operating and business models
  • Patient-centricity to the core
  • The increasing role of digital
  • The biggest challenges ahead for the Pharma industry

16.50 Panel: Hold on to Your Hats And Dust Off Your Chequebooks: Pharma BD and M&A Outlook in 2023 and Beyond

In today’s business of drug development, lucrative deals and newly formed partnerships can be just as important as scientific breakthroughs. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. While recently we have seen a modest rebound after a slow start in 2022, whether M&A activity continues will have a significant effect on which startups and drug programs get funded and advanced. Global leaders of pharma business development and M&A discuss the current climate, shifts in M&A strategies, the most exciting new areas of innovation, and their future outlook.

  • Through the last two years of the COVID-19 pandemic, a mainstay of the drug development community’s response has been collaboration, but will collaboration continue to be a critical paradigm for biopharmaceutical development?
  • Platform vs Product – Is there a preferred model when it comes to M&A?
  • What are the factors which can reinforce any biotech’s chance for an acquisition whatever their focus?
  • What has got the world’s largest companies excited in 2023, and what new innovations has the M&A leaders excited?
  • M&A looking forward – what sort of deals will dominate pharma pipelines, and what will the current inaccessibility to capital mean for future valuations?
Moderator: Robbie McLaren, Vice Chair of the Global Life Sciences Practice, Latham & Watkins
Matthias Müllenbeck, SVP Head Global BD & Alliance Management, Merck 
Jane Buus Laursen, Corporate VP Business Development, Novo Nordisk
Chris Sheldon, SVP, Global Head Business Development, GSK

Robbie McLaren, Partner, Latham & WatkinsMatthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaAJane Buus Laursen, Corporate Vice President Business Development, Novo NordiskChris Sheldon, SVP, Global Head Business Development, GSK

17:40 Drinks Reception


Day 2 – Thursday 4th May

09:00 LSX Welcome Address

Adam Griffiths, Senior Conference Director, Biotech Lead, LSX

09:05 New Approaches to Partnering with Novo Nordisk

Together with our partners, Novo Nordisk is committed to driving change in how the world sees, prevents, and treats diabetes, obesity and other serious chronic diseases. Taking the company in a new strategic direction requires an enhanced and renewed focus on partnering

  • What is the new direction for the company?
  • How to improve its pipeline?
  • How best to communicate this strategy to both internal and external stakeholders?
Moderator: Clive Cookson, Science Editor, Financial Times
John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk

John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordiskclivecookson

09:30 Panel: Biotech Leaders - Building a Galvanizing Culture & Successful Transatlantic Biotech

Growing a successful biotech into a lasting transatlantic business is no easy feat, and culture within an organisation can be its success or downfall. How do we build management teams and leadership structures to create an inspiring company culture, one that is felt throughout the business and lasts into the future? A multi-biotech panel discusses best practices, insights, and pro-tips into building an inspiring company with a growth mindset.

  • How does leadership shape company culture?
  • What do employees expect from their leadership in terms of culture in 2023 and how can we adapt?
  • How can company culture influence the hiring process?
  • How can a biotech begin to shape and mould its culture, into something new and established?
Moderator: Alexander Nuyken, Head Life Sciences Markets Europe, Middle East & Africa, JLL
Renee Aguiar-Lucander, CEO, Calliditas
Alex Zhavoronkov,
CEO, Insilico Medicine
Florian Brand,
CEO, atai Life Sciences
Lovisa Afzelius, Co-founder and CEO, Apriori Bio & Origination Partner, Flagship Pioneering

Alexander Nuyken, Head Life Sciences Markets Europe, Middle East & Africa, JLLRenee Aguiar-Lucander, CEO, Calliditas TherapeuticsAlex Zhavoronkov, CEO, Insilico Medicine (1)Florian Brand, CEO, ATAI Life SciencesLovisa Afzelius, CEO, Alltrna, & Origination Partner, Flagship Pioneering

10:30 Morning Break



11:10 Panel: Mitigating Risks and Attracting Rewards – How To Capitalise and Spot Innovation

The past three years saw venture capitalists invest $52 billion into therapeutic-based biotech companies globally, with $35 billion of this going into startups with transformative platform technologies. This session explores how investors evaluate “the next big thing” and what biotech founders with novel or innovative technologies can do to put their best feet forwards.

  •  How investors evaluate risk, particularly when looking at new fields or technologies
  • Appetite for investing in novel biotechnologies vs platforms
  • How investors keep on top of new ideas and what grabs their interest (and what turns them off)
  • How to identify “must have” science early on
  • Building an effective founding team including crucial roles and qualities
  • Where to deploy capital at the outset and why


Moderator: Paul Ainsworth, Director, Sterne Kessler
Simone Botti, Partner, INKEF Capital
Marianne Mertens,
Partner, Apollo Health Ventures
Sascha Berger,
General Partner, TVM Capital
Bonnie van Wilgenburg, Principal, Monograph Capital

Paul Ainsworth, Director, Sterne KesslerSimone Botti, Partner, INKEF CapitalMarianne Mertens, Partner, Apollo Health VenturesSascha BergerBonnie Van Wilgenburg, Principal, Monograph Capital Partners

12:00 Panel: Navigating the Public Markets – Adapting to Shift in Dynamics

US biotech stock prices declined toward the end of 2021, following a bull run that started in 2020. Investors who had recently rejoiced in positive clinical news from public companies now fled from risk. Small-cap exchange-traded funds (ETFs) struggled against ETFs skewed toward mid- to large-cap biotechs. Although the recent downturn has been less severe for businesses with commercial-stage assets, most have been negatively affected.

  • Perspectives on the public markets and impacts its having on private funding
  • What are later-stage investors advising their portfolio and growing later stage biotechs
  • Strategies to navigate the current volatile market
  • How to develop a long-term value mindset
Moderator: Philippa Gardner, Healthcare Analyst, Trinity Delta
Victoria Darbyshire, Equity Analyst, J.P. Morgan
Tom Burt, Partner, Sofinnova Partners
Cathal Friel, MD, Raglan Capital
Pierre-Louis Joffrin, Senior Associate, Jeito

Philippa Harder, Healthcare Analyst, Trinity DeltaVictoria Darbyshire, Equity Analyst, J.P. MorganTom Burt, Partner, SofinnovaCathal Friel, Managing Director, Raglan CapitalPierre-Louis Joffrin, CDO, Mogrify



11:10 Panel: Emerging Pharma Deal-Making Take Centre stage – Shifts in Focus and New Opportunities

An increasing number of new and emerging deal makers at small pharma continue to make their mark, and with a shift towards commercialising products to serve orphan populations and specialist-treated conditions in recent years. While industry giants dominate the news, how are the Heads of BD and M&A at growing and emerging pharma viewing the landscape? A panel of top emerging pharma dealmakers discuss focus, strategy, and vision for becoming a lead player in the industry.

  • Product acquisition vs in-licensing – what factors affect the decision-making process?
  • How do emerging Pharma differentiate themselves and source aligned innovation
  • New focus areas for 2023
  • Are emerging pharma deal-making strategies evolving?
Sandra von Meier, Head BD & Licensing, Debiopharm International SA
Pavithra Sundaresan,
VP Head of External Innovation, Grünenthal
Jukka Muhonen,
VP Global BD & Alliances, Orion Pharma
Eric Falcand, Vice President Global Head of Business Development, Servier Monde

Sandra von Meier, Head Business Development & Licensing, Debiopharm InternationalPavithra Sundaresan, Vice President, Head of External Innovation, Grünenthal Jukka Muhonen, Director of Global Business Development and Alliance Management, Orion CorporationEric Falcand, Vice President Global Head of Business Development, Servier Monde

11:50 Boehringer Ingelheim’s Research Beyond Borders 

Effective partnering of emerging science to bring therapeutic innovations to unserved patients.

  • Building a portfolio of projects inspired by external innovation
  • Portfolio strengthening through diversity
  • Delivering for unserved patients
Paul Nicklin, Director, Research Beyond Borders, Boehringer Ingelheim
Bernd Nosse, Global Head, BD&L Technologies and Research Beyond Borders, Boehringer Ingelheim

Paul Nicklin, Director, Research Beyond Borders, Boehringer IngleheimBernd Nosse, Global Head, BD&L Technologies and Research Beyond Borders, Boehringer Ingleheim

12:10 Panel: Early-Stage Pharma Partnering – Building a Strategy For Success

Partnerships with early-stage companies often spark some of the most innovative research and development collaborations in the healthcare industry. As breakthrough science continues to come from emerging biotech, the dynamics of innovation continue to evolve. The size, scale, expertise and connections of big pharma is still critical to the ecosystem, but are strategies changing? Pharma execs discuss how they are supporting innovation, sourcing and forming networks, and continuing to work to form win-win deals to partner with next wave biotechs.

  • How are the industry biggest players looking to source innovation sooner and support the youngest startups?
  • With a relative scarcity of capital are pharma seeing an increase in approaches for partnering?
  • What are the key considerations for companies in their partnering strategy approaching pharma? What is most commonly overlooked?
  • Which type of partnering at which stage?
Matthias Müllenbeck, SVP, Head Global Business Development & Alliance Management, Merck KGaA
Khatereh Ahmadi,
Head of Search & Evaluation European BD&L, MSD
Zaki Salanti, Head of S&E, Novo Nordisk
Rebecca Canter, Senior Director, Venture Sciences, Eli Lilly
Bernd Nosse, Global Head, BD&L Technologies and Research Beyond Borders, Boehringer Ingelheim

Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaAKhatereh Ahmadi, Head of Search and Evaluation Team, European BD&L Hub, MSDZaki Salanti, Head of S&E, Novo NordiskRebecca Canter, Senior Director, Venture Sciences, Eli LillyBernd Nosse, Global Head, BD&L Technologies and Research Beyond Borders, Boehringer Ingleheim



11:10 Panel: Planning for CGT Commercialisation: It Starts Sooner Thank You Think

Every decision throughout cell and gene therapy preclinical development is an opportunity to ensure future commercial success. From anticipating supply needs to planning ahead for commercial scale-up, what are the major factors that influence commercial readiness for these therapies at every stage?

  • Which practical strategies enable a seamless, adaptive manufacturing plan from preclinical development to commercialization
  • How integrated scale-down platforms can inform future scale-up decisions
  • Where the industry is headed next with data analytics, automation and technology
Moderator: Dean McAlister, Executive Vice President, Inizio Biotech
Adrien Lemoine
, CEO, Bloomsbury Genetic Therapies
Jan Thirkettle, CEO, Transine Therapeutics
Edward Samuel, EVP Technical Operations, Achilles Therapeutics
Rachel Hadfield, Managing Partner, MediStrava

Adrien Lemoine, CEO, Bloomsbury Genetic TherapiesJan Thirkettle, CEO, Transine TherapeuticsDean McAlister, Executive Vice President, Inizio BiotechEdward Samuel, EVP Technical Operations, Achilles TherapeuticsRachel Hatfield, Managing Partner, MediStrava

12:00 Panel: Attract, Retain, Develop – Building a Leading Executive Team & Board

Recruiting and attracting talent remains a key priority and increasing challenge as companies grow and the industry matures. Competition for roles with the right experience or training is higher than ever and with an increasing demand for hybrid or virtual workforce, how can biopharma organisations ensure the right people for their organisations. Executives discuss and tackle the biggest challenges in attracting, retaining talent and building out boards.

  • Small versus large company strategies and challenges
  • Should companies be building management teams and boards bigger and sooner as seen in the US??
  • How can companies work to maintain and retain top talent within their organisation?
Moderator: Justine Mcllroy, Partner, Coulter Partners
Keren Leshem,
CEO, OCON Healthcare
Sarah Shackleton,
Chief Talent Officer, Oxford Science Enterprises
Edwin Moses,
former CEO Ablynx; Chairman, European biotechs
Stefano Portolano,
CEO, Azafaros
Anatole Klepatsky,
COO, Orion Biotechnology

Justine Mcllroy, Partner, Coulter PartnersKeren LeshemSarah Shackleton, Partner, Marketing & Talent, Abingworth 300xEdwinMosesStefano Portolano, CEO, AzafarosAnatole Klepatsky, COO, Orion Biotechnology 1


12:50  Lunch Break

14:00 Panel: Diversity & Inclusion in Biotech and Pharma – Optimising Internal DE&I Processes to Create an Inspiring & Inclusive Workplace Environment

Diversity and inclusion within biotech and pharma, remain behind most other industries for DEI initiatives. With a hunger for companies to create new initiatives which can bring them closer to a more diverse and all-encompassing organisation, this panel will take a deep and candid dive into strategies and best practices for pharma and biotech companies looking to improve their diversity efforts across all areas of their businesses.

  • How can we create an environment of inclusive leadership to build principles from the top down?
  • Recruiting and retaining diverse talent
  • Development of employee workgroups to better understand the employee experience
  • Strategies and metrics to build and track internal initiatives
Moderator: Lisa Urquhart, Editor, Evaluate Vantage
Azurii Collier, Director, Enterprise Innovation, AbbVie; President, Women in Bio
Gerald Lee, Global Inclusion & Diversity Implementation Lead, GSK
Beatriz Rodriguez, SVP Talent, Inclusion & Diversity, Bayer
Roel Bulthuis, Managing Director, INKEF Capital
Quin Wills, CSO & Co-founder, Ochre Bio and Director, OUTbio

Lisa Urquhart, Editor, VantageAzurii Collier, Director, Enterprise Innovation, AbbVie and President-Elect, Women in Bio (WIB)Gerald Lee, Global Inclusion & Diversity Implementation Lead, GSKBeatriz Rodriguez, SVP Talent, Inclusion & Diversity, BayerRoel Bulthuis, Managing Director, INKEF CapitalQuin Wills, CSO & Co-founder, Ochre Bio and Director, OUTbio

15:10 Panel: Preparing for the Return of the Biotech IPO – 2023 and Beyond

Whether your planned listing date is six or 16 months away, communications play a critical role in a successful IPO — up to and beyond listing day — and need to be executed with precision. The financials are important, but any business is much more than a balance sheet. Investors care about the story behind the company, what’s driving success quarter over quarter and year over year, the priorities informing your business, the core values of your company, the quality metrics, and the leadership team powering the mission forward. For biotech and healthcare companies considering the public markets in 2023, the time to execute on IPO-readiness communications efforts is now. A major consideration for any company, executives who have taken their businesses public in the US discuss the decision and timing their listing, how they managed during in a period of huge disruption and travel restrictions and key success factors in taking European companies to Nasdaq.

  • Key considerations for companies looking to tap the US public markets
  • What skills and experience are necessary to bring on to your board and management team for life on US public markets?
  • How have biotechs who have successfully undergone an IPO during the downturn navigated the process?
  • The European discount – is the perception of European companies being undervalued (or US companies overvalued) a reality?
  • What does your communications planning need to include for IPO-readiness?
Moderator: Gregg Beloff, Managing Director, Danforth Advisors
Tim Haines, Managing Partner, Abingworth Life Sciences
Linden Thomson,
Lead Manager, Healthcare Franchise, AXA Investment Managers
Lone Henriksen,
CEO, CS Medica
Houman Ashrafian,
Managing Partner, SV Health Investors

Gregg Beloff, Managing Director, Danforth AdvisorsTim Haines, Managing Partner, Abingworth Life ScienceLinden Thomson, Lead Manager, AXA IM Framlington BioTech Fund, Head, Healthcare Franchise, Co-Head, Global Equity, AXA Investment ManagersLone Henriksen, CEO, CS Medica Houman Ashrafian, Managing Partner, SV Health Investors

16:00 Close of Congress